Takeda Pharmaceutical Company Limited (NYSE:TAK) on Thursday shared topline results for the Phase 3 comparing zasocitinib (TAK-279) to Bristol-Myers Squibb Co.'s (NYSE:BMY) Sotyktu (deucravacitinib) in adults with moderate-to-severe plaque psoriasis (PsO).
Head-To-Head Trial Meets Endpoints In the LATITUDE Atlas head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16.
The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment (sPGA) 0 at week 16.
Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified.
Investigators Highlight Skin Clearance Results Read Also: Jury Hits Takeda With $885 Million Antitrust Verdict "In this head-to-head study, zasocitinib clearly demonstrated superior skin clearance compared with deucravacitinib, highlighting clinically meaningful differences within the oral treatment class," said Linda Stein Gold, principal investigator for the LATITUDE Atlas study.
